secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0000950170-25-058956
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo
--------------------------------------------------------------------------------

- BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.
- Median duration of response 28 months; 58.3% of responders maintained CR at 24 months by K-M.
- 97.3% of patients free from progression to muscle-invasive bladder cancer at 24 months; 91.6% cystectomy-free.
- No Grade 3+ treatment-related adverse events or deaths; median resolution of any TRAE was one day.
- Cohort P (Ta/T1 without CIS): 90.5% high-grade recurrence-free survival at 3 and 9 months (n=24).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025058956/0000950170-25-058956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025058956/ck0001991792-20250426.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-058956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer